Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18369Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Bourantas, K. L. | en |
| dc.contributor.author | Hatzimichael, E. C. | en |
| dc.contributor.author | Makis, A. C. | en |
| dc.contributor.author | Chaidos, A. | en |
| dc.contributor.author | Kapsali, E. D. | en |
| dc.contributor.author | Tsiara, S. | en |
| dc.contributor.author | Mavridis, A. | en |
| dc.date.accessioned | 2015-11-24T18:52:12Z | - |
| dc.date.available | 2015-11-24T18:52:12Z | - |
| dc.identifier.issn | 0902-4441 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18369 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Disease Progression | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Immunoenzyme Techniques | en |
| dc.subject | Interleukins/*analysis | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Myeloproliferative Disorders/*blood | en |
| dc.subject | Tumor Markers, Biological | en |
| dc.subject | Tumor Necrosis Factor-alpha/*analysis | en |
| dc.subject | beta 2-Microglobulin/*analysis | en |
| dc.title | Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10414450 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1600-0609.1999.tb01845.x/asset/j.1600-0609.1999.tb01845.x.pdf?v=1&t=h0uocodl&s=d7ae427fd8349f5f31d9c635bb8dd1a2f5f42feb | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1999 | - |
| heal.abstract | Whereas beta-2-microglobulin (beta2M) has mainly been used as a prognostic factor in patients with lymphoproliferative disorders, some studies have reported the value of beta2M in myeloproliferative disorders (MPD). In order to investigate a potential role in the pathogenesis of MPD and to find a possible value as indicators in monitoring the course of the disease, we measured beta2M, TNF-alpha, IL-1alpha, IL-1beta, IL-2, sIL-2R, IL-6 and IL-10 in 55 patients with MPD, at diagnosis and during the course of the disease. In progressive disease and particularly when transformation to acute leukemia occurred, high levels of beta2M, IL-2 and sIL-2R were found in all patients; the elevation was progressive, which suggests a potential prognostic usefulness in the individual patient. | en |
| heal.journalName | Eur J Haematol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Bourantas-1999-Serum beta-2-microgl.pdf | 685.21 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
